Clinical Trial

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
Protocol Amendment History 29 amendments
This ClinicalTrials.gov record has been amended 29 times since 2024-03-19; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2024-06-06
Trial Details
NCT Number NCT06328777
Lead Sponsor Cabaletta Bio
Conditions Systemic Sclerosis, Scleroderma
Enrollment 12 participants
Start Date 2024-07-02
Primary Completion 2029-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-22